Open AccessThis article is
- freely available
Tumor-Associated Glycans and Immune Surveillance
Winthrop P. Rockefeller Cancer Institute and Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Stephan Angeloff Institute of Microbiology, BAS, Sofia 1113, Bulgaria
* Author to whom correspondence should be addressed.
Received: 18 April 2013; in revised form: 18 April 2013 / Accepted: 6 June 2013 / Published: 17 June 2013
Abstract: Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that bridge innate immune surveillance and adaptive antitumor immunity in clinical applications. T-cells, being a part of the adaptive immune response, are the most popular component of the immune system considered for targeting tumor cells. However, for TACAs, T-cells take a back seat to antibodies and natural killer cells as first-line innate defense mechanisms. Here, we briefly highlight the rationale associated with the relative importance of the immune surveillance machinery that might be applicable for developing therapeutics.
Keywords: monoclonal antibodies; immunotherapy; cancer; mimics; vaccine; TACA; glycans; tumor; carbohydrate
Citations to this Article
Cite This Article
MDPI and ACS Style
Monzavi-Karbassi, B.; Pashov, A.; Kieber-Emmons, T. Tumor-Associated Glycans and Immune Surveillance. Vaccines 2013, 1, 174-203.
Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. Tumor-Associated Glycans and Immune Surveillance. Vaccines. 2013; 1(2):174-203.
Monzavi-Karbassi, Behjatolah; Pashov, Anastas; Kieber-Emmons, Thomas. 2013. "Tumor-Associated Glycans and Immune Surveillance." Vaccines 1, no. 2: 174-203.